Citation Impact
Citing Papers
Oxidative Stress
2017 Standout
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging
2023 Standout
Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress
2017 Standout
Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial
2015
Vildagliptin: a new oral treatment for type 2 diabetes mellitus
2008
Hepatocellular carcinoma
2016 Standout
ROS in cancer therapy: the bright side of the moon
2020 Standout
Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis
2016
Obesity and inflammation: the linking mechanism and the complications
2016 Standout
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
2013
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
2012
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
2020 Standout
Type 2 diabetes
2017 Standout
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
2010
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
2009
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis
2016
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
2014
Type 2 diabetes mellitus
2015 Standout
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
2014 Standout
Cancer-related inflammation and treatment effectiveness
2014 Standout
ROS and the DNA damage response in cancer
2018 Standout
Glycaemic control in type 2 diabetes: Targets and new therapies
2009
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Stress Regulates Aquaporin-8 Permeability to Impact Cell Growth and Survival
2016
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
2008 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
Alogliptin: a new addition to the class of DPP-4 inhibitors
2009
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
2017
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes
2016
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
2016
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
p62/SQSTM 1—Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer
2016
Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta‐analysis
2016
Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
2013
The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies
2021 Standout
Green synthesis of zinc oxide nanoparticles using Hibiscus subdariffa leaf extract: effect of temperature on synthesis, anti-bacterial activity and anti-diabetic activity
2014 Standout
The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis
2018 Standout
Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials
2014
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Addition of dipeptidyl peptidase‐4 inhibitors to insulin treatment in type 2 diabetes patients: A meta‐analysis
2017
A review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials
2018
Linagliptin treatment in subjects with type 2 diabetes with and without mild‐to‐moderate renal impairment
2014
Works of Q. Shao being referenced
Sustained Efficacy and Reduced Hypoglycemia during One Year of Treatment with Vildagliptin Added to Insulin in Patients with Type 2 Diabetes Mellitus
2008
Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with Metformin
2008
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trial
2011
Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients
2015
Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus
2012
One‐year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
2012
Nrf2 is a potential therapeutic target in radioresistance in human cancer
2013